Copyright © 2005, European Society of Cardiology
Aging and biomedicine 2005: Where should we go from here?
Medizinische Poliklinik, Departement für Innere Medizin, Universitätsspital, Rämistrasse 100, CH-8091, Zürich, Switzerland
* Tel.: +41 1 255 5663; fax: +41 1 255 8747. Email address: barton@usz.ch
Received 28 February 2005; accepted 7 March 2005
| The first 10% of the full text of this article appears below. |
 |
1. Demographics of aging: the next 50 years |
|---|
Aging has become a central issue in science and society in view of demographic changes anticipated in the next decades due to longevity and low birth rates [1–3]. The steady growth of the world's population from approximately 2.5 billion in 1950 to 6.4 billion today is expected to increase even further to more than 9 billion by 2050 [4] (Fig. 1). The reasons for living longer [5] involve a decline in old-age mortality [6] due to advances in disease management and drug discovery, which have been made possible through continued economic stability. However, despite these advances, today's clinical practice faces an increasing number of geriatric patients with multi-morbidity that
|
2. Aging theories–all for one and one for all? |
|---|
|
3. Cardiovascular aging: a point of no return? |
|---|
|
4. Aging-associated "diseases": prevention rather than treatment |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Barton, M. R. Meyer, and E. Haas Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women: Does Aging Limit Therapeutic Benefits? Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1669 - 1672. [Full Text] [PDF]
|
|